NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on surgical solutions for neurological disorders, announced on May 22, 2026, that it will amend and restate its financial statements for the quarter ended March 31, 2026. The restatement corrects a one-time revenue overstatement of approximately $0.5 million, which was initially reported as $2.4 million in revenue. The error was identified during a post-release review on May 18, 2026, and was attributed to a customer order modification on a product shipment at the end of the quarter.
The restatement results in a reduction of gross profit by approximately $0.3 million and an understatement of operating loss and net loss by the same amount. Importantly, no prior periods were impacted, and the company's cash position as of March 31, 2026, remains unchanged. The company has also initiated measures to improve its internal controls over financial reporting.
NeuroOne reaffirmed its product revenue guidance for fiscal year 2026 of at least $10.5 million. Dave Rosa, CEO of NeuroOne, stated, “This one-time correction does not change our revenue projections for the year. Our operations remain strong, our growth strategy is unchanged, and we continue to anticipate product revenue for fiscal 2026 of at least $10.5 million.” The company expects to file an amendment to its Form 10-Q within the next few weeks.
This restatement highlights the importance of accurate revenue recognition in the medical technology sector, where financial transparency is critical for investor confidence. For NeuroOne, the correction does not alter its broader growth trajectory or ongoing business activities. The company continues to focus on its minimally invasive electrode technology platform, which includes four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. Additionally, NeuroOne is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The restatement serves as a reminder to investors and industry observers of the need for rigorous financial oversight, especially for companies navigating complex revenue recognition scenarios. NeuroOne's swift action to correct the error and its reaffirmation of guidance may mitigate concerns about the company's financial health. However, the company's ability to maintain compliance with Nasdaq listing requirements and achieve its growth projections remains subject to risks outlined in its SEC filings.
For more information about NeuroOne and its technology, visit nmtc1.com. The company's forward-looking statements, including those related to fiscal 2026 revenue guidance, are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
